- EMS-Chemie reported an Ebit of CHF 291 million for the first half of the year.
- The reported Ebit exceeded the estimated CHF 284.5 million.
- Net sales for the first half amounted to CHF 1.09 billion.
- Net sales figures fell short of the estimated CHF 1.13 billion.
- Analyst recommendations include 1 buy, 7 holds, and 1 sell.
A look at Ems-Chemie Holding Ag Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Ems-Chemie Holding Ag presents a promising long-term outlook. With a high Resilience score of 5, the company demonstrates strong ability to withstand economic uncertainties and market volatilities, providing stability for investors. Additionally, a solid Dividend score of 4 indicates a good potential for regular and consistent dividend payments, making it an attractive option for income-focused investors.
Furthermore, Ems-Chemie Holding Ag is positioned well in terms of Momentum and Growth, scoring 4 and 3 respectively. This suggests that the company is experiencing positive momentum in its operations and has the potential for future growth opportunities. While the Value score of 2 indicates that the stock may not be considered undervalued, the overall outlook for Ems-Chemie Holding Ag appears positive, especially for investors seeking a balanced mix of growth and income.
Summary: Ems-Chemie Holding AG is a company specializing in performance polymers, high-grade chemical intermediates, fine chemicals, and protective products. It serves industries such as automotive, transportation, and textiles with a diverse range of products.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
